Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$743K Sell
7,723
-591
-7% -$59.1K 0.11% 103
2025
Q4
$809K Sell
8,314
-890
-10% -$76.4K 0.11% 107
2025
Q3
$655K Sell
9,204
-53
-0.6% -$3.53K 0.09% 109
2025
Q2
$553K Sell
9,257
-246
-3% -$13.5K 0.07% 110
2025
Q1
$499K Sell
9,503
-499
-5% -$28K 0.07% 109
2024
Q4
$550K Sell
10,002
-1
-0% -$53 0.08% 117
2024
Q3
$503K Sell
10,003
-86
-0.9% -$3.97K 0.07% 115
2024
Q2
$464K Buy
10,089
+561
+6% +$23.9K 0.07% 111
2024
Q1
$419K Buy
9,528
+70
+0.7% +$3.09K 0.06% 114
2023
Q4
$396K Buy
9,458
+658
+7% +$27.7K 0.06% 112
2023
Q3
$390K Buy
8,800
+127
+1% +$5.9K 0.07% 111
2023
Q2
$414K Sell
8,673
-295
-3% -$13.3K 0.08% 110
2023
Q1
$353K Sell
8,968
-46
-0.5% -$1.67K 0.07% 119
2022
Q4
$318K Sell
9,014
-40
-0.4% -$1.14K 0.06% 127
2022
Q3
$251K Buy
9,054
+638
+8% +$22.2K 0.05% 134
2022
Q2
$294K Sell
8,416
-109
-1% -$3.91K 0.06% 125
2022
Q1
$354K Sell
8,525
-3,233
-27% -$150K 0.07% 114
2021
Q4
$449K Buy
11,758
+294
+3% +$11.9K 0.08% 97
2021
Q3
$437K Buy
11,464
+668
+6% +$22.7K 0.07% 110
2021
Q2
$392K Buy
10,796
+1,475
+16% +$40.6K 0.06% 110
2021
Q1
$261K Buy
9,321
+436
+5% +$10.4K 0.05% 136
2020
Q4
$215K Buy
+8,885
New +$205K 0.04% 156

Other funds holding IRMD

CIM LLC's IRMD Position: Q1 2026 in Review

CIM LLC reduced its iRadimed (IRMD) stake by 7.1% in Q1 2026, selling an estimated $59.1K and leaving 7,723 shares worth $743K. The position accounts for 0.11% of the portfolio, ranked #103.

CIM LLC first reported a position in IRMD in Q4 2020 and has held it in 22 quarters since. The position peaked at $809K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • CIM LLC held 7,723 shares of iRadimed worth $743K as of Q1 2026.
  • CIM LLC sold 591 iRadimed shares in Q1 2026, an estimated $59.1K.
  • iRadimed made up 0.11% of CIM LLC's portfolio in Q1 2026, its #103 holding.
  • CIM LLC first reported a position in iRadimed in Q4 2020 and has held it in 22 quarters since.
  • CIM LLC's iRadimed position peaked at $809K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on CIM LLC's 13F filing for Q1 2026, filed 18 May 2026.